Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1‐year Phase 1/2 clinical trialRaphael Schiffmann, Derralynn Hughes, Martha R. Charney et al.|Journal of Inherited Metabolic Disease|2019Cited by 137